NASDAQ · EXEL
Exelixis, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for EXEL has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.79 | $0.84 | $0.71 | 5 |
| Dec 2026 | $0.81 | $0.87 | $0.73 | 5 |
| Mar 2027 | $0.79 | $0.81 | $0.75 | 3 |
| Jun 2027 | $0.82 | $0.84 | $0.80 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · The Motley Fool · RTTNews- Zacks · 10 h agoExelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesAlthough the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Zacks · 10 h agoExelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesExelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 27, 9:00 AM EDTIDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- MarketBeat · Oct 26, 1:50 PM EDTBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockGLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space. Bristol-Myers Squibb (NYSE
- The Motley Fool · Oct 24, 7:20 PM EDTForget the FDA Delay: 3 Reasons Exelixis Is Still a BuyRegulators in the U.S. extended the review period for Exelixis’ request to approve a new cancer drug.
- Zacks · Oct 22, 9:00 AM EDTExelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseExelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 16, 8:45 AM EDTWhy Exelixis (EXEL) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks · Oct 15, 11:10 AM EDTWhy Exelixis (EXEL) is Poised to Beat Earnings Estimates AgainExelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks · Oct 8, 8:40 AM EDTHere's Why Exelixis (EXEL) is a Strong Value StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- RTTNews · Oct 1, 5:04 AM EDTBiotech Stocks At 52-Week Highs – PGEN, EXEL, TWST, HNGE, PBYI(RTTNews) – The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.
- Zacks · Sep 30, 8:45 AM EDTExelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Zacks · Sep 24, 11:48 AM EDTCould Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Exelixis, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.